Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...

Financial writer recommends buying ARK Genomic Revolution ETF (ARKG) for potential growth in 2025. Explore more here.

Tom Lilly Appreciation Night is another winning night for Cedar Rapids Xavier. Saints get a stern test from Cedar Rapids ...

Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward ...

Novo Nordisk and Eli Lilly will dominate the obesity drug market long-term, says Mizuho's Jared Holz Jared Holz, Mizuho, ...

Health-care companies rose as traders rotated back into the sector amid optimism about blockbuster drugs. Novo Nordisk shares rose by more than 8% for one of their biggest gains in recent years after ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.

The Danish drug company said an experimental weight-loss shot helped patients lose over one-fifth of their bodyweight. Novo's U.S. and [Europe-listed s ...

The Danish pharma giant posted impressive data for amycretin one month after the disappointing readout of CagriSema.

Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...